Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4782-4788

  Troke, Peter F ^a   Hockey, Hans P ^b   Hope, William W ^c  

^a Old Court ^*  (United Kingdom)

^b Biometrics Matters Ltd   (New Zealand)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPOGLYCEMIA; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SYSTEMIC MYCOSIS; YEAST;

ADULT; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FUNGI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; MYCOSES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 80052859006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01083-10     Document Type: Article

References (44)

1. Ally, R., et al. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33:1447-1454.
2. Andes, D. 2004. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist. Updates 7:185-194. (Pubitemid 39024519)
3. Andes, D. 2003. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr. Opin. Invest. Drugs 4:991-998.
4. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
5. Andes, D., A. Pascual, and O. Marchetti. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
6. Bruggemann, R., et al. 2009. Reviews of anti-infective agents: clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458.
7. Bruggemann, R. J., et al. 2010. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic hematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 65:107-113.
8. D'Argenio, D., and A. Schumitzky. 1997. ADAPT II: a program for simulation, identification, and optimal experimental design, user manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
9. Denning, D. W., et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
10. Drusano, G. A. L. 2009. Editorial commentary: how many steps along the path is too far? Clin. Infect. Dis. 50:3.
11. Drusano, G. L., et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760.
12. Espinel-Ingroff, A., E. Johnson, H. Hockey, and P. Troke. 2008. Activities of voriconazole, itraconazole, and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J. Antimicrob. Chemother. 61:616-620.
13. Goodwin, M. L., and R. H. Drew. 2008. Antifungal serum concentration monitoring: an update. J. Antimicrob. Chemother. 61:17-25.
14. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
15. Hope, W. W., and G. L. Drusano. 2009. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin. Microbiol. Infect. 15:602-612.
16. Howard, A., J. Hoffman, and A. Sheth. 2008. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann. Pharmacother. 42:1859-1864.
17. Ikeda, Y., et al. 2004. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75:587-588.
18. Imhof, A., D. J. Schaer, U. Schanz, and U. Schwarz. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739-742.
19. Johnson, E., A. Espinel-Ingroff, A. Szekely, H. Hockey, and P. Troke. 2008. Activity of voriconazole, itraconazole, fluconazole, and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int. J. Antimicrob. Agents 32:511-514.
20. Johnston, A. 2003. The pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56:1.
21. Kullberg, B. J., et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442. (Pubitemid 41483809)
22. Liu, P., et al. 2007. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob. Agents Chemother. 51:3617-3626.
23. Miyakis, S., S. J. van Hal, J. Ray, and D. Marriott. 2009. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933.
24. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
25. Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
26. Perfect, J. R., et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
27. Prentice, A. G., et al. 2008. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. British Committee for Standards in Haematology, London, United Kingdom.
28. Purkins, L., et al. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
29. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56:10-16.
30. Purkins, L., et al. 2003. The pharmacokinetics and safety of intravenous voriconazole: a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56:2-9.
31. Roffey, S. J., et al. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741.
32. Sambatakou, H., B. Dupont, H. Lode, and D. W. Denning. 2006. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am. J. Med. 119:527e17-527e24.
33. SAS Institute. 2003. SAS/STAT users guide, version 8.2. SAS Institute, Inc., Cary, NC.
34. Segal, B. H., et al. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus criteria. Clin. Infect. Dis. 47:674-683.
35. Seibel, N., et al. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-3324.
36. Smith, J., and D. Andes. 2008. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30:167-172.
37. Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
38. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. B Biomed. Sci. Appl. 691:441-448.
39. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
40. U.S. Food and Drug Administration. 2001. Voriconazole briefing document. FDA Antiviral Drugs Advisory Committee, Rockville, MD. http://www.fda.gov/ohrms/ dockets/AC/01/briefing/3792b2-01-Pfizer.pdf.
41. Vandewoude, K., et al. 1997. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. 41:2714-2718.
42. Walsh, T., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
43. Walsh, T. J., et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
44. Walsh, T. J., et al. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.